The store will not work correctly when cookies are disabled.
YIII-DOTATOC
ID: ALA1791314
Chembl Id: CHEMBL1791314
Max Phase: Preclinical
Molecular Formula: C65H92N14O18S2Y+3
Molecular Weight: 1510.57
Molecule Type: Small molecule
Associated Items:
Associated Targets(non-human)
Molecule Features
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
Drug Indications
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanisms of Action
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Calculated Properties
Molecular Weight: 1510.57 | Molecular Weight (Monoisotopic): 1509.5197 | AlogP: ┄ | #Rotatable Bonds: ┄ |
Polar Surface Area: ┄ | Molecular Species: ┄ | HBA: ┄ | HBD: ┄ |
#RO5 Violations: ┄ | HBA (Lipinski): ┄ | HBD (Lipinski): ┄ | #RO5 Violations (Lipinski): ┄ |
CX Acidic pKa: ┄ | CX Basic pKa: ┄ | CX LogP: ┄ | CX LogD: ┄ |
Aromatic Rings: ┄ | Heavy Atoms: ┄ | QED Weighted: ┄ | Np Likeness Score: ┄ |
References
1. Deshmukh MV, Voll G, Kühlewein A, Mäcke H, Schmitt J, Kessler H, Gemmecker G.. (2005) NMR studies reveal structural differences between the gallium and yttrium complexes of DOTA-D-Phe1-Tyr3-octreotide., 48 (5): [PMID:15743193] [10.1021/jm0496335] |